EndoPAT®️ system may help measure cardiovascular risk from breast cancer treatment

SAN ANTONIO — The Endo-PAT2000 assay may be a simple way to measure vascular elasticity in outpatients after treatment with aromatase inhibitors, Douglas Yee, MD, director of the Masonic Cancer Center, professor of medicine and pharmacology at the University of Minnesota, and a HemOnc Today Editorial Board member, told HemOnc Today at the San Antonio Breast Cancer Symposium.